Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl TAIFUN for Breakthrough Cancer Pain
NCT00822614Phase 3Unknown
- Sponsor
- Akela Pharma Inc.
- Start
- Dec 2008
- Primary completion
- Dec 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fentanyl in breakthrough cancer pain (BTcP), sponsored by Akela Pharma Inc.. Status: unknown.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00822614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00822614.